» Articles » PMID: 15199316

HIV-associated Neuromuscular Weakness Syndrome

Overview
Journal AIDS
Date 2004 Jun 17
PMID 15199316
Citations 10
Affiliations
Soon will be listed here.
Abstract

Objective: To investigate progressive, severe neuromuscular weakness associated with lactic acidosis in some HIV-infected patients after exposure to nucleoside reverse transcriptase inhibitors (NRTI).

Methods: HIV-associated neuromuscular weakness syndrome (HANWS) was retrospectively identified and classified based on the level of diagnostic certainty: possible (progressive weakness owing to neuromuscular disease), probable (progressive neuromuscular weakness with documented exclusion of confounding causes), or definite (progressive weakness and electrophysiological or pathological evidence of neuromuscular pathology).

Results: Of 69 patients identified with HANWS, 27 had definite HANWS, 19 probable, and 23 possible. In 44 patients with documented follow-up, 16 required intubation and nine died. There was a marginal association between death and hyperlactatemia (P = 0.061). At onset of neurological symptoms, 68 were receiving antiretroviral therapy, including stavudine for 61 (89.7%). Serum lactate level was elevated (> 2.2 mmol/l) in 30/37 (81%), with a trend towards an association between hyperlactatemia and stavudine usage (P = 0.087). In 25, neurological symptoms occurred after antiretroviral therapy discontinuation (median, 14 days). Electrophysiological studies (n = 24) indicated sensorimotor neuropathy in 20 patients and myopathy in three. Nerve biopsy (n = 9) revealed axonal degeneration and inflammation in three, mixed axonal and demyelinating lesions in three, and primary axonal neuropathy in three. Of 15 muscle biopsies, three revealed inflammation and four mitochondrial abnormalities.

Conclusions: A severe neuromuscular weakness syndrome may occur in HIV-infected individuals. The association with hyperlactatemia and NRTI exposure supports mitochondrial toxicity as a pathogenesis. In some, the onset of neurological symptoms lagged significantly after discontinuation of antiretroviral therapy, suggesting that different etiological mechanisms may underlie these cases.

Citing Articles

Changes health-related quality of life in HIV-infected patients following initiation of antiretroviral therapy: a longitudinal study.

Dutra B, Ledo A, Lins-Kusterer L, Luz E, Prieto I, Brites C Braz J Infect Dis. 2019; 23(4):211-217.

PMID: 31344351 PMC: 9428026. DOI: 10.1016/j.bjid.2019.06.005.


Variations in plantar pressure and balance in HIV-infected children in antiretroviral therapy.

da Silva Pontes L, Callegari B, Magno L, Moraes A, Silva B, Manso K Sci Rep. 2019; 9(1):4344.

PMID: 30867540 PMC: 6416285. DOI: 10.1038/s41598-019-41028-0.


Neuropsychiatric Effects of HIV Antiviral Medications.

Treisman G, Soudry O Drug Saf. 2016; 39(10):945-57.

PMID: 27534750 DOI: 10.1007/s40264-016-0440-y.


Neurological and psychiatric adverse effects of antiretroviral drugs.

Abers M, Shandera W, Kass J CNS Drugs. 2013; 28(2):131-45.

PMID: 24362768 DOI: 10.1007/s40263-013-0132-4.


Longitudinal lactate levels from routine point-of-care monitoring in adult Malawian antiretroviral therapy patients: associations with stavudine toxicities.

Chagoma N, Mallewa J, Kaunda S, Njalale Y, Kampira E, Mukaka M Trans R Soc Trop Med Hyg. 2013; 107(10):615-9.

PMID: 23926161 PMC: 4023278. DOI: 10.1093/trstmh/trt074.